MedPath

A I/II phase study of chemotherapy using irinotecan plus L-OHP plus S-1 treatment (SOXIRI) for unresectable advanced pancreatic cancer

Not Applicable
Recruiting
Conditions
unresectable advanced pancreatic cancer
Registration Number
JPRN-UMIN000012975
Lead Sponsor
the university of tokushima
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

(1) infusion of blood products within 7days (2) not first line treatment (3) severe Allergie (4) much ascites or pleural effusion (5) infection (6) diarrea (7) ileus (8) neuropathy (9) severe heart disorder (10) neuropsychiatric disorder (11) idiopathic pulmonary fibrosis or Idiopathic interstitial pneumonia (12) brain metastasis (13) pregnancy case (14) unsuitable case

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath